Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide - Reuters
Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOUHVrZXRmM2ROWFJHajI1NlhzSVM5RFFIczZqY29KMXlIdjRFZFpYcnBIMzBjQldVUUVqN05ZdlZyLVE2TkhYYVVFM1djLVZYcTlGVE5qZjJfQnhnczVZdHd5WmpQZ1k3dEtRMGZXM0ttb1otTWEtMFU1bTNKczI5UWFURUVTRXVLaVYtdVdGcm9BSnU1R2w1Y052SGhTeGpkSDQ4UzRyOGJEdm5CTElzcVRKZHptNUE?oc=5" target="_blank">Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Samsung, affiliates commit $1 billion to KKR-backed Helix Digital AI buildout - Reuters
Samsung, affiliates commit $1 billion to KKR-backed Helix Digital AI buildout Reuters
September 28, 2026 at 11:56 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMBayer to invest $2.2 billion in new US pharma site - Reuters
Bayer to invest $2.2 billion in new US pharma site Reuters
October 2, 2026 at 07:19 PMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMBioNTech to shutter three sites in Germany as no buyers emerge - Reuters
BioNTech to shutter three sites in Germany as no buyers emerge Reuters
September 28, 2026 at 08:00 PM